Osvaldo Reyes Selected Research

CIGB-300

6/2018	Characterization of low-abundance species in the active pharmaceutical ingredient of CIGB-300: A clinical-grade anticancer synthetic peptide.
2/2015	Bio-analytical method based on MALDI-MS analysis for the quantification of CIGB-300 anti-tumor peptide in human plasma.
4/2012	Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localization.
10/2011	CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research.
9/2008	CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.
1/2008	Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice.
10/2004	Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Osvaldo Reyes Research Topics

Disease

15	Neoplasms (Cancer) 06/2018 - 10/2004
4	Prostatic Neoplasms (Prostate Cancer) 01/2019 - 12/2007
2	Eclampsia 10/2017 - 06/2015
2	Lung Neoplasms (Lung Cancer) 01/2013 - 04/2012
1	Endometritis 01/2022
1	Rupture 01/2022
1	Surgical Wound Infection 01/2022
1	Fever (Fevers) 01/2022
1	Pain (Aches) 05/2019
1	Pre-Eclampsia (Preeclampsia) 10/2017
1	Carcinoma (Carcinomatosis) 08/2016
1	Infections 01/2016
1	HIV Infections (HIV Infection) 01/2016
1	Hemolysis 06/2015
1	HELLP Syndrome 06/2015
1	Body Weight (Weight, Body) 02/2015
1	Hypertensive Crisis 01/2014
1	Ischemia 02/2012
1	Breast Neoplasms (Breast Cancer) 01/2008
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 12/2005
1	Sepsis (Septicemia) 01/2003
1	Dengue (Dengue Fever) 03/2002

Drug/Important Bio-Agent (IBA)

13	Peptides (Polypeptides)IBA 06/2018 - 03/2002
7	CIGB-300IBA 06/2018 - 10/2004
6	Proteins (Proteins, Gene)FDA Link 10/2017 - 03/2002
5	VaccinesIBA 01/2019 - 12/2005
4	Gonadotropin-Releasing Hormone (GnRH)FDA Link 01/2019 - 12/2007
3	Testosterone (Sustanon)FDA Link 01/2019 - 12/2007
3	Casein Kinase II (Casein Kinase 2)IBA 09/2008 - 10/2004
2	Pharmaceutical PreparationsIBA 06/2018 - 10/2011
2	NucleophosminIBA 04/2012 - 10/2011
2	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 09/2008 - 10/2004
2	AndrogensIBA 01/2008 - 12/2007
2	Hormones (Hormone)IBA 01/2008 - 12/2007
2	Cyclic PeptidesIBA 01/2008 - 10/2004
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2022
1	ChlorhexidineIBA 01/2022
1	Saline SolutionIBA 01/2022
1	SolutionsIBA 01/2022
1	Lidocaine (Xylocaine)FDA LinkGeneric 05/2019
1	Tramadol (K315)FDA LinkGeneric 05/2019
1	Diazepam (Valium)FDA LinkGeneric 05/2019
1	Diclofenac (SR 38)FDA LinkGeneric 05/2019
1	AntibodiesIBA 01/2019
1	Amino Acids FDA Link 06/2018
1	CIGB-552 peptideIBA 10/2017
1	Antineoplastic Agents (Antineoplastics)IBA 10/2017
1	montanide ISA 51IBA 08/2016
1	proteoliposomesIBA 08/2016
1	VimentinIBA 01/2016
1	EnzymesIBA 06/2015
1	Hydralazine (Apresoline)FDA LinkGeneric 01/2014
1	Labetalol (Normodyne)FDA LinkGeneric 01/2014
1	AntioxidantsIBA 01/2013
1	LipidsIBA 01/2013
1	SecretagoguesIBA 02/2012
1	gamma- aminobutyryl- 2- methyltryptophyl- 2- methyltryptophyl- 2- methyltryptophyl- lysinamideIBA 02/2012
1	Growth Hormone (Somatotropin)IBA 02/2012
1	Cell-Penetrating PeptidesIBA 01/2008
1	Protein Kinases (Protein Kinase)IBA 10/2004
1	cell-binding peptide P-15IBA 10/2004
1	lipopolysaccharide-binding proteinIBA 01/2003
1	LipopolysaccharidesIBA 01/2003

Therapy/Procedure

7	Therapeutics 01/2019 - 10/2004
2	Immunotherapy 12/2007 - 12/2005
1	Curettage 10/2017
1	Castration 08/2016
1	Intravenous Administration 02/2015
1	Lasers (Laser) 02/2015